Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.
VP 16-213 in standard doses is active against a number of solid tumors. Its penetration into the cerebrospinal fluid (CSF) is very limited at these dose levels. In 10 patients treated with high-dose VP 16-213 (0.9-2.5 g/m2), CSF levels of up to 0.54 microgram/mL were detected. In two patients with central nervous system (CNS) metastases of small cell lung cancer (SCLC) a response was seen after 1.0 and 1.5 g/m2 intravenously. High-dose VP 16-213 can possibly play a role in the treatment of CNS metastases of SCLC. Its application in late intensification regimens as a form of prophylaxis of CNS metastases should be investigated.
D000328:Adult; D000368:Aged; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000134:cerebrospinal fluid / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000134:cerebrospinal fluid / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid*; D006801:Humans; D007275:Injections, Intravenous; D008175:Lung Neoplasms; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D014057:Tomography, X-Ray Computed
D005047:Etoposide; D011034:Podophyllotoxin